Dicerna Pharmaceuticals, Inc. DRNA : Cambridge, MA-based Dicerna is focused on the discovery and development of subcutaneously delivered RNAi-based pharmaceuticals using its GalXCTM RNAi platform for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna, which is expected to report first quarter 2017 results on May 8, has a negative earnings ESP of 3.08%. Dicerna is a Zacks Rank #4 stock.